Boston Braces for Groundbreaking Findings at ISPOR 2025!

In an exciting announcement from OM1, the forefront of real-world data and AI in mental health for life sciences, a highly anticipated poster presentation is set to unveil significant insights regarding Glucagon-like Peptide 1 Receptor Agonists (GLP-1s) and their potential link to suicidal ideation (SI). Lead by Jessica Probst, Principal in Real World Evidence, this study reveals crucial data that could change perceptions around these medications.

Key Findings Challenge Existing Beliefs!

Scheduled for Wednesday, May 14, from 4:00 to 7:00 PM, with a heated discussion period from 6:00 to 7:00 PM, this session promises to challenge prevailing notions. Despite existing cautionary warnings about GLP-1s—often prescribed for diabetes and obesity—the study finds no statistically significant rise in suicidal ideation following treatment initiation among patients.

Why This Research Is Vital!

The implications are profound. Obesity treatments with GLP-1s carry warnings about suicidal ideation, raising fears and potentially blocking access to treatments for many patients. With this research, OM1 questions whether these warnings could be more harmful than beneficial, especially for those in vulnerable populations seeking help.

Innovative Techniques Uncover Hidden Insights!

Harnessing advanced natural language processing (NLP) tools, OM1 delves deeper into unstructured clinician notes, revealing mental health insights often overlooked in traditional data analyses. This innovative approach demonstrates the power of AI and real-world evidence (RWD) in enhancing pharmacovigilance and ensuring public health safety.

What This Means for Regulatory Bodies!

The findings are poised to influence key stakeholders by: supporting regulatory evaluations, improving risk-benefit communications, and aiding in effective signal detection and mitigation strategies.

About OM1: Pioneering Healthcare Innovation!

OM1 stands at the forefront of revolutionizing healthcare through data-driven technology and insights. With a rich portfolio in personalized medicine and real-world evidence research, OM1's expertise—backed by a diverse team of scientists, engineers, and clinicians—promises to continue shaping the future of mental health and patient care.